Evidence map›Paper›PMID 33375352›Full record

ArticleAntibiotics (Basel, Switzerland)2020

An

Adam Baraka, German M Traglia, Sabrina Montaña, Marcelo E Tolmasky, Maria Soledad Ramirez

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Emergence ofMicrobiology spectrum · 2026
    Article
  2. Deciphering the genomic landscape of novelFrontiers in microbiology · 2026
    Article
  3. Genomic insights into the adaptation of Acinetobacter johnsonii RB2-047 to the heavy metal-contaminated subsurface mine environment.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024
    Article
  4. Article
  5. Review
  6. Synergistic Role of Biofilm-Associated Genes and Efflux Pump Genes in Tigecycline Resistance of Acinetobacter baumannii.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  7. Antibiotics (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Molecular Epidemiology of Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2021
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Adam BarakaCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
German M TragliaDepartamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, MVD, Montevideo 11800, Uruguay.ORCID 0000-0002-4780-5311
Sabrina MontañaLaboratorio de Bacteriología Clínica, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, Buenos Aires 1120, Argentina.
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-6298-7811
Maria Soledad RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-9904-7890
California State University, Fullerton · USHospital de Clínicas "José de San Martín" · ARUniversidad de la República de Uruguay · UY

Funding

Minority Health and Health Disparities International Research Training ProgramT37MD001368 · NIMHD · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2005 to 2024
$3.9M
DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851k
NIAID NIH HHS R15 AI047115NIH HHS 2R15AI047115NIH HHS SC3GM125556NIMHD NIH HHS 2T37MD001368NIMHD NIH HHS T37 MD001368
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acinetobacter non-baumanniiantimicrobial resistanceresistome

Identifiers

PMID33375352
PMCPMC7823295
OpenAlexW3114970104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.